

#### **Patient Identification Strategies for Neuromodulators**

Charles E. Argoff, MD

# **Title & Affiliation**

- Charles E. Argoff, M.D.
- Professor of Neurology
- Albany Medical College
- Director, Comprehensive Pain Center
- Director, Pain Management Fellowship
- Albany Medical Center



#### Disclosure

Nothing to disclose



# **Learning Objectives**

- Describe patient selection criteria for implantable pain therapies.
- Compare systemic and intrathecal drug delivery.
- Differentiate FDA-approved intrathecal analgesics.



# WHAT TO DO WITH PATIENTS WITH SEVERE CHRONIC PAIN?





# **Neuromodulation Defined**

The International Neuromodulation Society defines therapeutic neuromodulation as "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body." In appropriate patients, this growing class of therapies, in common use since the 1980s, can help restore function or relieve symptoms that have a neurological basis.

https://www.neuromodulation.com/neuromodulation-defined- accessed 8/21/20



# Why Neuromodulation?

- Testable
- Completely reversible
- Non-destructive
- No limitation to future therapy



# **Neuromodulation Approaches to Mention**

- SCS
- DRG
- PNS
- ■HF-10
- Intraspinal analgesics



#### **Are These Patients Good Candidates?**

- 53 year old male with post laminectomy pain syndrome with persistent right lower extremity pain
- •43 year old female with small fiber neuropathy associated with celiac disease
- 36 year male with fibromyalgia and pain everywhere on 200mg of morphine daily
- 40 year old female with CRPS that has "spread" to her entire body
- 40 year old female with CRPS that affects right lower extremity
- 32 year old male with traumatic brachial plexopathy




## **Principles of Screening**

- Identify and accurately select patients who will achieve long-term success following implantation of a SCS or ITDD system
- Goals should be discussed and defined by both the physician and patient BEFORE the trial
- Goals are not uniform across patients they need to be defined on a case-bycase basis
- Trial should approximate as closely as possible the conditions of long-term therapy
- SCS represents a SINGLE element in overall long-term pain management for a given patient



# Intrathecal Therapy for Chronic Noncancer Pain Placement in Interventional Pain Algorithms




DRGS, dorsal root ganglion stimulation; HF10, high frequency stimulation; PNfS, peripheral nerve field stimulation; PNS, peripheral nerve stimulation; SCS, spinal cord stimulation.

Green arrows indicate affirmation or positive response; red arrows signify negative response. Adapted from Deer TR, et al. *Neuromodulation*. 2017;20(2):96-132.


Painweek

#### Pain Management: A More Flexible Approach\*





#### Patient Referral Finding the Right Partner in Interventional Pain Management



#### Patient Selection Pretrial Workup



Painweek.

#### Medical history

- -Review diagnosis, comorbidities, previous treatments, and outcomes
- -Social issues (eg, home environment, insurance)

#### Physical examination

- -Spinal and anatomic factors
- -Device-related limitations

#### Patient education

- -Informed consent
- -Potential benefits and risks
- -Caregiver education
- -Compliance requirements
- -Identification of realistic functional goals

# Patient Selection Criteria for Implantable Pain Therapies: SCS and IT Drug Delivery

- Failure of more conservative therapies
- Further surgical intervention is not indicated
- Absence of serious untreated drug habituation
- Psychological evaluation and clearance for implantation has been obtained
- No contraindications to implantation exist.
  - sepsis, coagulopathy, etc.
- Successful screening trial



#### **Patient Selection**


#### **Elements of Psychological Evaluations**

- Informed consent and rationale for psychological evaluation
- Current concept of pain and beliefs about treatment
- Current psychological consequences of pain
- Current emotional status
  - Depression, anxiety
  - -Sleep, appetite
  - Suicidal ideation
  - Irritability, anger, guilt

- Review of mental health-related therapies
- Observation of pain behaviors
- Psychosocial and developmental history
- Clinical evaluation of psychological and cognitive functioning
- Standardized psychological testing
  - -eg, MBMD, MMPI-2

## Gate Theory and SCS

 SCS Implanted Near Dorsal Column Stimulates the Pain-inhibiting Nerve Fibers Masking Painful Sensation With a Tingling Sensation (Parathesia)






#### **SCS: Mechanisms of Action**

- Releases certain neurotransmitters that cause vasodilation- helpful for angina, PVD and CRPS
- Increases levels of GABA... in patients with allodynia (CRPS), GABA levels are decreased in the CSF
- Blocks sympathetic outflow. For some CRPS patients, abnormal activity of the SNS is responsible for a lot of their symptoms, and SCS can help significantly with temperature and skin color changes as well as with pain.



## **Screening Paradigm for SCS**





# **Clinical Factors**

- Indication
  - -Neuropathic pain
  - -Static
- Disease Etiology
  - -Disease likely to progress not a good candidate
- Pain Distribution
  - -Multi site and broad pain patterns often require more leads and electrodes
  - -Back pain will likely require current fractionalization
- Patient Factors
  - -Anatomy
  - -Physiology
  - -Selection



# Diagnoses

- In our patient population, we use SCS for FBSS (low back or neck), CRPS, chronic pain s/p crush injury, and phantom limb pain.
- However, this doesn't mean that any patient who carries one of these diagnoses is a good candidate...



#### **Neuropathic vs Nociceptive Pain**

- Patients with neuropathic pain respond better to SCS. Peripheral neuropathy has published success rates of nearly 75%, whereas FBSS (which is both neuropathic + nociceptive) has published success rates closer to 60%.
- Nociceptive pain is more responsive to anti-inflammatories and opioid medication, whereas neuropathic pain typically is not.




#### **Duration of Symptoms**

- Inverse relationship b/n the chronicity of the pain and the outcomes of SCS
- For FBSS, patients who received their SCS within 2 years of symptoms onset had a success rate of 85%. Those with pain >15 years only had a 9% success rate.<sup>1</sup>
- CRPS- considered before central sensitization has set in/ as soon as other treatments have failed.<sup>2</sup>

 Kumar et al 2013. Impact of Wait Times on Spinal Cord Stimulation Therapy Outcomes. Pain Practice 2013
 Kumar et al 2011. Neurosurgery 69;566-78.

Painweek




#### **Stimulation Paradigms**

- Paresthesia-based (P-SCS)
- Paresthesia-free (PF-SCS)
- Burst (B-SCS)
- High Frequency (HF-SCS)
- Evoked Compound Action Potential (ECAP-SCS)
- Dorsal Root Ganglion (DRG-S)




# **Potential Painful Stimulation**

- Dorsal Roots
  - SCS of specific dorsal roots may result in paresthesia in 1 or 2 corresponding dermatomes
  - May produce painful stimulation
- Ventral Roots and Horn
  - SCS of ventral roots or horn will likely produce painful motor stimulation
- Stimulation of Nerve Fibers in Dorsal Ligamentum Flavum may Produce Painful Stimulation





#### **Programs Can Be Activity or Pain-Based**



**EXAMPLE** 



#### **Essential Information from Trial**

- Is there adequate paresthesia overlap of the pain?
- Can coverage be obtained with multiple contacts?
- Did coverage of different pain areas require different electrode combinations?
- Stimulation parameters to achieve the ideal results?
- Were there any adverse effects of stimulation?
  - -Painful stimulation, root/trunk stimulation
- What degree of analgesia was achieved?
- Were the goals of the trial as determined by the patient and physician met?




#### **SCS – The Biggest Lies Ever Told**

"This device is going to relieve all of your pain" "Don't worry, the permanent stimulator will work better than the trial"




# **SCS** Trial




#### Painweek.

## **Trial Lead Placement**

#### CAUDA EQUINA







## **SCS Trial... Realistic Expectations**





# **SCS** Trial

- The trial process is not ideal
- Positionality: the leads are in the epidural space and float around a bit. With change in position, there is a change in coverage.
- Type of sensation?
- Patients must be able to understand that the purpose of the trial is 'does this help with your pain/function'
- Trial duration infection risk? No shower?!
- Generally speaking, the trial success rate is 70%, however in the WC population this number is lower.



# **Trial Follow Up**

- 1) Pain relief: what percentage? Did the stimulator cover the whole painful area? Reprogramming...
- 2) Function: hard because of the positionality, but look for sitting/standing tolerance, walking. Not going to be able to assess things like bending/lifting during the trial.
- 3) Medication usage: did they need less medication? Short trial period, plus procedural pain, may be hard to assess



# **SCS Implant**

- 2 ways to implant- surgical and percutaneous
- One of the variables in how patients respond during a trial is the amount of space- (CSF)- between the electrode and the cord.
- Paddle lead eliminates this, and gives a greater area of coverage. Also, because the lead is fixed, there is less chance of breakage.









#### **Outcomes: FBSS- Pain**

Only 2 Randomized Controlled Trials, both industry sponsored!

- 1. North et al 2005: 45 FBSS pts- compared SCS to re-operation; at 3 year follow up SCS had a more favorable outcome than re-op, nearly obviated the need for re-op, and sig less meds. \*\*67% of the re-op patients then crossed over to SCS
- 2. Kumar et al 2007: 100 FBSS patients randomized to CMM vs SCS with 2 year f/u. 48% of SCS vs 9% of CMM had 50% improvement in pain. Also with better function and QOL
- 3. Overall for FBSS, **50-60%** of patients get >=50% better

Turner JA et al. Spinal Cord Stimulation for Patients with Failed Back Surgery Syndrome or Complex Regional Pain Syndrome: A Systematic Review of Effectiveness and Complications. Pain 2004;108:137-47.



### **Outcomes: FBSS- Function/Med Intake**

- No RCT has looked specifically at function
- 3 case series did show improvements in function
- Functional outcome is also a function of timing- Study looked at long term outcomes of SCS; noted that function was most improved in patients who were implanted <1 year after onset of symptoms<sup>1</sup>
- North study- SCS group used significantly less opioids than the re-operation group- 45%<sup>2</sup>

<sup>1</sup>Kumar K et al. Spinal Cord Stimulation is Effective in Management of Complex Regional Pain Syndrome 1: Fact or Fiction. Neurosurgery 2011;69(3):566-78.

<sup>2</sup>North RB et al. Spinal Cord Stimulation versus Repeated Lumbosacral Spine Surgery for Chronic Pain: A Randomized Controlled Trial. Neurosurgery 2005;56:98-107.

#### **Pain**week,

# What About WC?

- Study compared ONLY WC patients with FBSS who had a SCS, were treated in a pain clinic, or had no specialized treatment.
- Trial success rate was 53%.
- Overall, this study showed no benefit to SCS, either in terms of long term pain relief, function, or return to work status.

Turner JA et al. Spinal Cord Stimulation for Failed Back Surgery Syndrome: Outcomes in a Workers' Compensation Setting. Pain 2010;148:14-25/



# **Outcomes: FBSS-RTW**

- Several studies have looked at FBSS patients' return to work after SCS: in one, 8/23 resumed work<sup>2</sup>, in a second 4/32 resumed<sup>3</sup>, in a third 15% of the 60 patients who received a SCS returned, vs 0/44 who did not get implanted<sup>4</sup>.
- In the outcome paper specifically looking at SCS for FBSS in WC, fewer than 10% of patients in any group were working at 12 months

- 2. Dario A et al. Treatment of failed back surgery syndrome. Neuromodulation 2001;4:105-110
- 3. Ohnmeiss DD et al. Prospective outcome evaluation of spinal cord stimulation in patients with intractable leg pain. Spine 1996;21:1344-51.
- 4. Kumar K et al. Treatment of chronic pain iwht spinal cord stimulation versus alternative therapies: cost-effectiveness analysis. Neurosurgery 2002;51:106-16.

# **Outcomes: CRPS**

- One Randomized Controlled Trial!
- 24/36 patients got SCS + PT, 18 only PT
- SCS group had reduced pain (-3.6/10 compared to +0.2), overall 39% of the SCS group were 'much improved', and all 24 had improved HR QOL at 6 months
- No improvement in functional status in either group
- At 1 year follow up, results the same. At 5 year follow up, results became less impressive, but 20 of the SCS patients still had improved global perceived effect and pain relief.
- \*\*95% of the patients who had SCS would opt for it again

Kemler et al. Spinal Cord Stimulation in Patients With Chronic Reflex Sympathetic Dystrophy. NEJM 2000;353:618-24.

# **Outcomes: CRPS**

- Prospective study followed 84 consecutive patients with CRPS who underwent SCS implantation<sup>1</sup>
- SCS was determined to be an effective long-term treatment (12 years) for 63% of patients
- Average decrease in pain 25-30% from baseline, but 59% rated their pain as much or very much improved.
- No data on function or medication intake
- Meta-analysis performed in 2006 showed 67% of CRPS patients got at least 50% better following SCS, with sig improved QOL and functional mobility<sup>2</sup>

Geurts JW et al. Spinal Cord Stimulation for CRPS 1; A Propsepctive Cohort Study with Long-Term Follow up. Neuromodulation 2013;16(6):523-9. Journal of Pain and Symptoms Management 2006;31(4):S13-19.



# **Outcomes: CRPS/RTW**

Several studies have looked at CRPS patients' return to work after SCS: in one study, 41% of 24 patients returned,<sup>1</sup> in another 5/25 returned<sup>2</sup>, and one study had a 70% RTW rate<sup>3</sup>

- 1. Calvillo O et al. Neuroagumentation in the treatment of CRPS of the upper extremity. Acta Orthop Belg 1998;64:57-63.
- 2. Kumar K et al. Spinal cord stimulation is effective in management of complex regional pain syndrome I: fact or fiction. Neurosurgery 2011;69:566-78.
- 3. Harke H et al. Spinal cord stimulation in sympathetically maintained complex regional pain syndrome type I with severe disability. Eur J Pain 2005;9:363-73.

### What About Depression?

- Severe depression is seen as a contra-indication to SCS.
- However, unlike physical functioning, the level of depression has been shown to markedly improve following SCS implantation.<sup>1-31</sup>
- Pre-implantation depression scores have not been shown to affect long term outcomes.





# **How to Improve Outcomes?**

- Smart patient selection
- Psychological factors/eval
- TIMING- Much better response at <2 years for FBSS
- For CRPS, before dystrophic changes are present. Best results seen within a year of symptom onset.<sup>1</sup>
- For CRPS, SCS should be considered as soon as alternative therapies have failed; even within the first 3 months.<sup>2</sup>

Kumar et al. Neurosurgery 2011;69;566-78.
 Poree et al. Neuromodulation 2013;16(2):125-41

**Pain**Week.



### **Do the Results Wane Over Time?**

- Results vary. Some studies show that the effect decreases 25-50% over 2 years, others only see a slight decrease in efficacy over time. This may be due to progression of disease, or electrode dislocation/ breakage.
- In 2011 an outcome analysis of patients with paddle electrodes was publishedin patients with CRPS, more than 50% of patients still had greater than 50% pain relief at 4.4 years, and 77.8% of them would choose to get implanted again.

www.neuromodulation.org





# **Overview Of Systemic vs Intrathecal Therapy**

#### Systemic drug delivery

- Drug distributed via bloodstream
- Drug interacts with receptors throughout the body
- Oral dosing produces peaks and troughs in plasma levels
- Relatively high daily dosages — High systemic side effect risk and drug-elimination load
- Concerns about adherence, abuse, and diversion

#### Intrathecal drug delivery

- Implantable pump sends drug via catheter to intrathecal CSF
- Drug targeted to spinal receptors
- Steady-state around-the-clock dosing can be achieved
- Relatively low daily dosages
- Reduced systemic side effects and low drug-elimination load
- Potential for better adherence and less diversion

CSF, cerebrospinal fluid.

Bagnall D. Phys Med Rehabil Clin N Am. 2010;21(4):851-858; Deer TR, et al. Pain Physician. 2010;13(3):E175-E213; Hayek SM, et al. Pain Physician. 2011;14(3):219-248; Onofrio BM, et al. Mayo Clin Proc. 1981;56(8)516-520; Prager J, et al. Neuromodulation. 2014;17(4):354-372.



### **New PACC Recommendations**

fulation: Technology at the Neural In

	1016
	Ronied October 27, 3916 Review 12, 3916 Accepted December 3, 3016
anied Mech 4 2016 Related Mey 23, 2016 A coupled Mey 23, 2016	A Decision 27, 2016 Revision November 27, 2016
The Polyanalgesic Consensus Conference The Polyanalgesic Consensus and Guidelines	The Polyanalgesic Consensus Conference Control Data (1997) And
DOI: 10.1111/mer.12550	
The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug (PACC): Recommendations Best Practices and Guidelines	The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal (PACC): Recommendations for Intrathecal
Locic Consensus Constanting	a heanaldesic consense intrathecdi
palyanaldesic constant an Intratilecal Stars	The Polyanaryeste Lations for Intratine
The Polyanary Jations of managed allines	The conditions to control
inc a perommendations and Guidennes	Becommended in anoving Saley
	(DACC): necon for improving
The Polyanalgesic Consension Intrathecal Drug (PACC): Recommendations on Intrathecal Drug (Infusion Systems Best Practices and Guidelines Infusion Systems E. Pope, MD <sup>+</sup> ; Salim Hayek, MD, PhD <sup>+</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Jason E. Pope, MD <sup>+</sup> ; Salim Hayek, MD, PhD <sup>+</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Isic Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>+</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Eric Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Fire Buchser, MD <sup>+</sup> ; Salim Hayek, MD <sup>++</sup> ; Timothy R. Deer, MD <sup>+</sup> ; Salim Hayek, M	The Polyanalgeste (PACC): Recommendations for Intratice (PACC): Recommendations for Intratice Delivery: Guidance for Improving Safety Delivery: Guidance for Improving Safety
Systems Dest MD, PhD'	
Infusion System Hayer, mer	Delivery
InfuSion 9, 50% as the set of the	Delivery: Carlos Control Contr
Timothy R. Deer, MD*; Jason E. Pope, MD*; Sam Eldabe, MD*; Anjum Bux, MD*; Eric Buchser, MD*; Sam Eldabe, MD*; Jose A. De Andrés, MD, PhD, EDRA*; Michael Erdek, MD*; Jose A. De Andrés, MD, PhD, EDRA*; Michael Erdek, MD***; Dennis Patin, MD*9; Jay S. Grider, PhD, MBA**, Daniel M. Doleys, PhD***; Dennis Patin, MD*9; Jay S. Grider, PhD, MBA**, Difference, MD****; Dennis Patin, MD*9; Jay S. Grider, PhD, MBA**, Difference, MD****; Jose S. Jacobs, PhD***; Tony L. Yaksh, PhD***; Jose S. Jacobs, PhD***; Mark S. Wallace, MD***; Joshua Prager, MD****;	Mitigating (MD*); Jason E. Pope, MD <sup>+</sup> ; Salim M. Hayes, MD*; Timothy R. Deer, MD*; Jason E. Pope, MD <sup>+</sup> ; Michael Erdek, MD*; Tim J. Lamer, MD <sup>+</sup> ; Ilir Elias Veizi, MD*; Michael Erdek, MD*; Tim J. Lamer, MD <sup>+</sup> ; Jay S. Grider, PhD, MBA <sup>++</sup> ; Michael Saulino, N. Halace, MD <sup>++</sup> ; Jay S. Grider, PhD, MBA <sup>++</sup> ; Michael Saulino, N.
Timothy K. Decis Eric Buchser, MD + Michael Erdek, MD Polove PhD***	Intering a second E. Pope, Most had Erdek, MD
anium Bux, MD, Ento, PhD, EDRA , Michael M, Doneys,	Timothy R. Deer, MD*; Jason E. Pope, mD, Juan Erdek, MD+, Timothy R. Deer, MD*; Ilir Elias Veizi, MD*; Michael Erdek, MD+, Tim J. Lamer, MD*; Ilir Elias Veizi, MD*, MD, MBA+*; Robert M. Levy, Mark S. Wallace, MD*; Jay S. Grider, PhD, MB+**; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Stefan Schu, Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Stefan Schu, Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD**; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD***; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD***; Steven M. Rosen, MD***; Michael Saulino, N Mark S. Wallace, MD***; Michael Saulino, N MARK Saulino, MB***; Michael Saulino, N M
Anjun De Andrés, MD, Fild, and Scrider, PhD, MBA*; Johnson Jose A. De Andrés, MD, Fild, Scrider, PhD, MBA*; Johnson Dennis Patin, MD <sup>55</sup> ; Jay S. Grider, PhD, HD <sup>4++</sup> ; Marilyn S. Jacobs, PhD <sup>7++</sup> ; Tony L. Yaksh, PhD <sup>4++</sup> ; Joshine Diwan, MD <sup>5555</sup> ; Marilyn C. Bergere, MD, PhD <sup>555</sup> ; Mark S. Wallace, MD <sup>54++</sup> ; Sudhir Diwan, MD <sup>5555</sup> ;	Timothy R. Destors, Ilir Elias Velzi, the php MBA++; Robert Line N
	Time L Lamer, MD , att low S Grider, PhD, Michael Saulino,
Pannie Patin, MD , attt. Tony L. Yaksii, and MDIIII: Joshua 1 5669.	TIM J. Wallace MD Jay S. M. Bosen, MD TIPP FDRAS
Dennis Clacobs PhD 'sss Mark S Wallace, mbu to Diwan, MD	Mark S. Wallace, Steven M. Rose MD, PhD, Firth Cobu
Marilyn S. Jacob Ann PhD <sup>999</sup> ; Main S. Ann++++; Sudhir Diwari,	Prager, MD 14 Loco A. De Andres, map+*** Stefan Schu
Leuronce Poree, MD, the Occar DeLeon, MD His MD*****	Timothy R. Deer, MD'; Lii Elias Veizi, MD'; MuBatt, Robert M. Leey, Tim J. Lamer, MD'; Ilii Elias Veizi, MD'; MuBatt, Robert M. Leey, Mark S. Wallace, MD't; Jay S. Grider, PhD, MBatt, Michael Saulino, N Mark S. Wallace, MD't; Jay S. Grider, PhD, PhD, FIPP, EDRASS Joshua Prager, MD't+; Jose A. De Andrés, MD, PhD, FIPP, EDRASS Joshua Prager, MD't+; Jose A. De Andrés, MD, PhD, FIPP, EDRASS
Anjum Bux, MD, Y=MD, EUKA, Y, MMBA*S, Daniel M. Docey-H. Jose A. De Andrés, Jay S. Grider, PhD, MBA*S, Daniel M. Docey-H. Dennis Patin, MD*S; Jay S. Grider, PhD, Malace, MD***, Joshua Prager, MD****; Marilyn S. Jacobs, PhD***, Tony L. Yaksh, PhD***; Jawrence Poree, MD, PhD***, Mark S. Wallace, MD****; Joshua Prager, MD****; Richard Rauck, MD****; Mcar DeLeon, MD****; Sudhir Diwan, MD****; Richard Rauck, MD****; Helena M. Gazelka, MD*****; Richard Rauck, MD****; Helena M. Gazelka, MD*****;	Tim J. Lamer, MD, Ti, Jay S. Grider, FHD, Messe, Michael Saumo, Mark S. Wallace, MD <sup>14</sup> ; Jay S. Grider, FHD, Messe, MD, PHD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PHD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PHD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup> Joshua Prager, MD <sup>144</sup> ; Jose A. De Andrés, MD, PhD, FIPP, EDRA <sup>55</sup>
Richard Rauck, maki MD 1111; Helena MD 59999;	Abeion Gonzalez, Mekhail, MD, File
Marilyn S. Jacobs M.D. PhD <sup>999</sup> ; Mark Dr. MD <sup>++++</sup> , Sudhir Diwan, M. Lawrence Porce, M.D. PhD <sup>999</sup> ; Mark Dr. MD <sup>++++</sup> , Sudhir Diwan, M. Richard Rauck, MD <sup>1+++</sup> , Michael Leong, MD <sup>56565</sup> ; Steven M. Falowski, MD <sup>5994</sup> ; Michael Leong, MD <sup>56565</sup> ; Philip Kim, MD <sup>+++++++</sup> ; Michael Leong, MD <sup>56565</sup> ; Philip Kim, MD <sup>+++++++</sup> ; Michael Leong, MD <sup>56565</sup> ; Philip Kim, MD, Philetter, Demana Naidu, MD <sup>++++++</sup> ; Philip Kim, MD, Philetter, Demana Naidu, MD <sup>+++++</sup> ;	Mark S. Wallace, MD*, Steven M. Rosen, MD Joshua Prager, MD**, Steven A. De Andrés, MD, PhD, FIPP, EUKA Tony L. Yaksh, PhD***, Jose A. De Andrés, MD, MD, Stevers, Stefan Schu, David Abejon Gonzalez, MD***, Nagy Mekhail, MD, PhD\$555 Brian Simpson, MD****, Nagy Mekhail, MD, PhD\$555 Brian Simpson, MD****, Nagy Mekhail, MD, PhD
Steven MD <sup>++++++++</sup> MD <sup>+++++++</sup>	
Philip Kind AD Phu / Shaidu MU / AD SSIS	Different an important part of the participant to understand the party
a hort M. Levy, MD, attittt, Ramana Naida, Derruchoud, MD	to steep intrathecal therapy is that a is inherent for pain private steep with intrathecal therapy
Richard Rauck, MD <sup></sup> , rotest, Helena M. GB26555, Steven M. Falowski, MD <sup></sup> , rotest, Michael Leong, MD <sup>55555</sup> , Philip Kim, MD <sup>++++++++</sup> , Michael Leong, MD <sup>555555</sup> , Robert M., Levy, MD, PhD <sup>555555</sup> , Christophe Perruchoud, MD <sup>5555555949494</sup> , Samir Narouze, MD, PhD <sup>5555555</sup> , Christophe Perruchoud, MD <sup>555555594949494</sup> , Steven M. Rosen, MD <sup>+++++++</sup> , William S. Rosenberg, MD <sup>1++++++</sup> , Steven Saulino, MD, PhD <sup>5444444</sup> , Peter Staats, MD <sup>55555594944949</sup> , Steven Saulino, MD, PhD <sup>5444444</sup> , Dean Willis, MD <sup>+++++++</sup> , Elliot Krames, MD <sup>4+++++</sup>	Arithmetic State Stat
Porter Mchober and PhD999999 Chiller C Posenberg, MD congeneration	option is a viable of a viable of a vidence and mitigating and option of an analyzed and a vidence and mitigating of a vidence of the analyzed and the second control of the sec
ADSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS	manuscript, we explore the search was performed country and International Pharmatern to offer weights
Porter McRoberts, MD, Ph0ss5s5s, Christophe relations, MD <sup>TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT</sup>	
Steven M. Rosen, MD, PhoPstarres, peter Dark Mitter, Ellior Ruthers, Steven M. Rosen, MD, PhoPstarres, Poeter Dark Willis, MD, HITTT, Ellior Ruthers, MD*****; Dean Willis, MD, PhoPstarres, MD****; Nagy Mekhail, MD, PhoPstarres, Nagy Nagy Nagy Nagy Nagy Nagy Nagy Nagy	Methods X entral, Googde Scholar, Currents analysis, and conversions in-analysis and conversions in- cross-referenced and completed for evidence, analysis, and conversions in-analysis and conversions statements on safety for targeted instandanced wave and best packed recommendations to import and conversions statements on safety for targeted instandanced wave and best packed recommendations. The United Results: The Polyanalgesic Conservation Conference has made several best packed or each recommendation methods and montality associated with instandanced iterapy trough planks of of each recommendation of the experiment of concerns the energy has summers are of the transment of concern and and concerns the energy has a summer of the transment of concern and the energy has a summer of concerns the energy has a summer of the transment of concern and and concerns the energy has a summer of concerns the energy has a summer of the transment of concern and and concerns the energy has a summer of concerns the energy has a summer of the transment of concern and and concerns the energy has a summary of the energy has a summer of the transment of concerns the energy has a summary of the energy has a
atichael Saulino, MD, Wester, Dean Willis, MD, PhD	Biomed compiled for error and intrathecal triespy
Michael MD******** Mekhail, MD, Fild	
Lisa J. Stearns, up55555999; Nagy Michael and Agorithmic process	and consensus surveine in Consensus Conference has through all phases of manual second mendation.
Michael Sadumers, MD******; Dearn Weikhail, MD, PhD  Michael Sadumers, MD*****; Dearn Mekhail, MD, PhD  Marchael Sadumers, MD*****; Magy Mekhail, MD, PhD  Michael Sadumers, MD****; Magy Mekhail, MD, PhD  Michael Sadumers, MD*****; Magy Mekhail, MD, PhD  Michael Sadumers, MD****; Magy Mekhail, MD, PhD  Michael Sadumers, MD*****; MD*****; MD*****; MD*****; MD*****; MD*****; MD*****; MD*****; MD******; MD*****; MD*****; MD*****; MD*****; MD*****; MD******; MD*****; MD*****; MD*****; MD*****; MD******; MD*****; MD******; MD*****; MD****; MD*****; MD*****; MD*****; MD*****; MD****; MD****; MD****; MD****; MD*****; MD****; MD****; MD****; MD*****; MD****; M	coils devices as attements on safety i.e. Conference has made several devices on management. The conference has made several devices and conservence has made several devices and management. The conservence has not several devices and the several devices are required as a several and conservence are obtained with the several devices are obtained as a several and conservence are obtained with a several and conservence are obtained with the several devices are required to improve our convert pharmacoleteric and pharmacoleteric a
Marc Treatment of a patient-centric, sarely a group of experts to evaluate a	the second secon
WHICE Credition: Fina treatment is been generated when a patient-cettric. Law, and a second secon	Beautit: Into a constant associated warm seeming associated associated warm and the set of the
Introduction: The treatment is built performance/dataton force by an organization guide canonics Conference IPACI to guide and service and the service of the service IPACC organization of Conference IPACI to guide and charged to address the deficients and anomations energing struct the pervices IPACC organization IPAC and the service IPACI to guide and charged to address the deficient and anomations energing struct the pervices IPACC or IPAC and the service IPACI to guide and charged to address the deficient service energies to the service and degree of encommend address IDL And entropy of the service of the service of the service IPAC and the service of the service and degree of encommend address IDL And encommend the service of t	vice task the shoral therapy is a viable serviced to improve our content
Introductions, Functional Networks and Netwo	al Vec Isaan is transfered, therapy is a vacuum expanded to improve out of Conclusions instantiant optimizing optimizing and the improve out of Continued research and expansion optimizing and the start of Inframedia dang delivery, as this will undoubtedly improve safety and efficacy.
sic Consensus Contextual and under was designed to address the strategy and the strategy an	continued research and explosite will undoubtedly improve the
such des The current Process of the mifed publications of the amend to determine evidence and noncancer pain, with	in the storage of the
and An extensive Interature scenario the Interature, the panel connection, which was raised at with cancer, terminal interval	
Introduction: 2017, the intermittion Mealurine. Solid Constants Conference (PACID) solid provided to address the discontinue will encounters energing risks and approximate additional Solid Constants Conference (PACID) solid provided to address the discontinue (VIII), 2017 and Reserved Line (VIII), 2017 and	ous and street, ste 100, Char
side cars Size Advince PACCI to guide practice. Methods: The ACCC space way designed to adverse the defencies and practice proceedings of the adverse of the adve	out the address correspondence to Tesushy R, Deer, MD, President and CEO, The Center for Pain Ridel, Inc., 400 Court Street, Sile 100, Claudore address correspondence to Tesushy R, Deer, MD, President and CEO, The Center for Pain Ridel, Inc., 400 Court Street, Sile 100, Claudore address ad
for intrathecal medication choices and anects of intrathecal drug mension consensus points environment	the provident and CEO, The Center Con-
about localized or diffuse pain.	endergine to: Timothy R. Deer, ND, 11
ether localizes to an Results: The PACC has developed an algorithmic polycological and the pace in the ordence-based care. Consensus option, based on engention, was used to the pace in the date of instatecial dug deletery. Conduction: New algorithms and guidance have been established to importe care with the use of instatecial dug deletery. Conduction: New algorithms and guidance have been established to importe care with the use of instatecial dug deletery. Conduction: New algorithms and guidance have been established to importe care with the use of instatecial dug deletery. Conduction: New algorithms and guidance have been established to importe care with the use of instatecial dug deletery.	Addess collespond
Results: The wed care. Consensus opinion, one of the set of intratrictal on opinion of the set of intratrictal on opinion.	Indexmin Control from Radie Conductance Wei URA:
exidence based care. Commission was precised and the commission of the commission o	DocTDext® Constant for Pain Relief, Charleston, WY, USA
panel consultations and guidance have been seen to be a seen to be consultation with USA. Under	Octorer(P)     Center for Pain Relie (Chadrours), VII-V     Center for Pain Relier, Chadrours, VII-V     Summit Pain Relier, Santa Roia, C.A. USA     Summit Pain Relier, Center Medical Center, Case Western Reserve University, Cleveland, OH, USA     Summit Pain Relier, Center Marchael, March
Condusion: New ago of the second seco	<sup>4</sup> California Pajos Malence, Sanza Javak C. Carter, Care Western Reserved. <sup>5</sup> Samma Pajos Malence, Sanza Javak C. Sanza C. Sanza S. S
content and CEO. The Center for Pain Notes	Mayo Clinic Rochester, Mrk. Deriver Andread Center, Case Western Hells University School of Medical Center, Case Western Hells University School of Medical Center, Case Western Hells
increases Tamothy R. Deer, MD, Presucción	Veteranti Administration includi Care Medicine, Johns KM, CA, USA:
Address correspondence to	** Anestheskology and Charlesia, UC San Diego, San Lwey College of Medicine, Lexingues
	11 Department of Annual Services, University of Menualsy
ad com * Center for Pain Relief, Charleston, WV, USA * Center for Pain Relief, Charleston, GA, USA 	<ul> <li>Neurains Administration Mariane Medicine, Jahon Helper, AU UK.</li> <li>Hostenberg Genetic Mariane Strategy (School School Sc</li></ul>
<ul> <li>Contro To Run Radi Cruberton WK USA</li> <li>Sammer To Pan Nations, Sense Book, X. USA</li> <li>Sammer To Nations, Sense Book, X. USA</li> <li>Casa Wataneou Usavareni, Carantina K. Garantina McDoawili Regional Medical Center, Danville, NY, USA</li> <li>Sawathonas and Chronic Pana Meangements, McMarthan McDoawili Regional Medical Center, Danville, NY, USA</li> <li>New athonas and Pana Natagements, McMarthanoly, NY, Watani, Santani, Sawathona, Sawat</li></ul>	
* Summir Family, Outpering Reserve University, Outpering Reforming McDown Integration (Morges, and CHUV University) (Morges)	*** Concerning for the International Concentration Competition **** For Concerning Technic Strate Strate Competition **** Discretion France Strate Competition Concerning Concerning Concerning ***********************************
a switheria and Chronic Pain Markey ment Department, EHC Hospita,	<ul> <li>*** For Chair Parlian Park, PA USA:</li> <li>*** Madibian Park, PA USA:</li> <li>*** Madibian Park, PA USA:</li> <li>*** Mandbian USA:</li> <li>*** Mandbian USA:</li> <li>*** Mandbian USA:</li> <li>*** Mandbian USA:</li> <li>*** Valence Valence</li></ul>
<ul> <li>Land Shinki and David Kananganet Department, L.K. F. Varansen, S. Saint, Saint, Saint, S. Saint, Saint, Saint, Saint, Saint, Saint, S</li></ul>	Th Mounter and Pharmacology, and Pharmacology, and Ceneral Universitatio, where the sector of the se
The James Cook University Research University School & Model	<ul> <li>Anarbeiteleiteleite arthedicter, Inspilal unbei Spile</li> <li>Valette arthedicter, Inspilal unbei Spile</li> <li>Magaal Unbernetter, Guan Madel, Mahnin Spile</li> <li>New Netzenberk Klick, Universitätiskhum Dürektert Germany:</li> <li>Netzenbergerter, Spilalung, Germany: mysterpilal Wales, Cardiff, UK; and</li> </ul>
11 Valencia School of Medicine, John March 1997 School (School 1997)	111 Hospital Universitatio Content Universitätski Inikum Dussedon, opp
** Anesthesionogy and Month System, March 14: Health Care Pain Services, Letting 14: 14	Neurochiunglische hums Germany: Wales, Cardiff, UK; and
<ul> <li>The Jahrs Sond of Medicine, Holly Backson, Johns Hopkins (Directory)</li> <li>Water School of Medicine, Holly Marcine, Johnson Hopkins (Directory)</li> <li>Mater School of Marcine Heads Systems, TU, USK:</li> <li>Mathematic Marcine Heads Systems, Marcine Heads School of Medical University of Restricts (Colling of Links, School of Medical University)</li> </ul>	199 Hospital Universitäri V Universitäri kai Mautan Sussessi Neurochistopisek Känk, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitä Hospital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Hospital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital Kinkouroungery, Universitäri Kaspital et Wales, Card.#, UK; and 1995 Sana Kaspital et Kaspital

No. 4 Annovember y response to manimum y and the second of Medicine. Health accord with the second of Medicine, Ball and Caterial Cateria Medicine, Ball and Cateria Medicine, Ball and Cateria Cateria Medicine, Ball and Cateria Medicine, Ball and Cateria Cateria Medicine, Ball and Cateria Medicine and strengthal Up cky College, ningham, AL, USA; edicine Center, Los Angeles, CA, USA; edicine Center, Los Angeles, CA, USA; plogy, Un © 2017 International Neuromodulation Society

conveiley.com) DOI: 10.1111/ner.12579	Conference
e Polyanalgesic Con	sensus Conference ions for Intrathecal Drug Improving Safety and
a polyanalgesic con	ions for Intrathecal Bill
Pronyendat	ions to safety and
ACC): Recommended	Improving Sales
Bicks	tions for Intratilective and Improving Safety and pe, MD <sup>+</sup> ; Salim M. Hayek, MD, PhD <sup>+</sup> ; MD <sup>+</sup> ; Michael Erdek, MD <sup>**</sup> : er, PhD, MBA <sup>++</sup> ; Robert M. Levy, MD, PhD <sup>55</sup> er, PhD, MBA <sup>++</sup> ; Robert M. Levy, MD, PhD <sup>55</sup>
MD*: Jason E. Por	be, MD, Sael Erdek, MD**; MD, PhD <sup>59</sup>
nothy R. Deer, MD , Flias Veizi,	ND"; MRA#+; Robert M. Levy, MD. PhD+++;
ark S. Wallace, MD Steven M. R	osen, MD, PhD, FIPP, EDRA MD <sup>++++</sup> ;
shua Prager, MD +++ Jose A. De	Andres, MD****; Stefan Schu, MD
ony L. Yaksh, PhD	er, PhD, Mex**; Michael Saulino, PBD, Sen, MD***; Michael Saulino, PBD, Andrés, MD, PhD, FIPP, EDRA <sup>56</sup> ; An Vesper, MD****; Stefan Schu, MD <sup>+++</sup> ; chall, MD, PhD <sup>5555</sup>
ny L. Yaksh, PhD <sup>+++</sup> ; Jose AD <sup>91</sup> ; Ja avid Abejon Gonzalez, MD <sup>91</sup> ; Ja rian Simpson, MD <sup>++++</sup> ; Nagy Mel rian Simpson, MD <sup>++++</sup> ; Nagy Mel	osen, MD***; Michaelpp, EDRA <sup>939</sup> ; Andrés, MD, PhD, FIPP, EDRA <sup>939</sup> ; In Vesper, MD***; Stefan Schu, MD++++; chail, MD, PhDssss tof the pain traitment algorithm for drank disease states. The use of this is for pain traitment algorithm for drank disease states. The use of this is for pain physicise to understand risk accessment and misgation. In this is for pain physicise state with iterative disease. MEDLAE, and the physicise disease state is the information we
Introduction: Intrathecal therapy is an important par option is a viable treatment strategy, but it is inherer manuscript, we explore evidence and mitigating strat power literature search was performed	(Rust, interarrent algorithm for durance duesare tables. The use of non- tional particulations to understand risk assessment and magators. In this in for pain physicians to understand risk assessment and magators. In this pages to improve address with instructed the therp. Understand Physicians (Control of Control of Control of Control or overing January amount) Physicians the information we provering January amount of Physicians (Control of Control of Control overing January amount) Physicians (Control of Control of Control of Control overing January amount) Physicians (Control of Control of Control of Control overing January amount) Physicians (Control of Control of Contr
Introduction: In a wable treatment strategy, but it is inter-	egies to improve salivity to October 9, 2016, in PubMed, Eliteration was
manuscript, we explore evidence and through was performed	covering January 2011 Pharmaceutical Absolutions
stathods A robust man current Contents	I septemblis review, much
Methods: A local coople Scholar, Current Contral, Biomed Central, Google Scholar, Current Contrali- cross-referenced and compiled for evidence, analysi and consensus statements on safety for targeted int and consense statement	rathecal therapy delivery.
Results: The Polyanalgesic Consensus Contraction	Control, service, with the intervice of the service
morbidity and mortality association of the second s	therapy rooms are detend for each recursion. By assummers are detend for each recursion of ancer- and nonzancer elable part elableby and option for the treatment of ancer- and pharmacodynamic model of insprove safety and ethacy.
Conclusion: Include and expert opinion are required	improve safety and emcacy-
Vice Table Vice Table Intrathecal therapy is a viable available Continued research and expert opinion are required intrathecal drug delivery, as this will undoubtedly	t p-Th
	CEO, The Center for Pain Belef, Inc., 400 Court Steed, Ste 100, Challenson, WV, USA. Email: DocTor
	crici. The Center for Pain Relief, Inc., 400 Court Part of
endence to: Timothy R. Deer, MD, President and	(Pan)
Address correspondence ad.com	
for Pain Relief, Charleston, WV, USN	Revenue University, Cleveland, OH, USA:
Summit Pain Alliance, Santa Hose Summit Pain Alliance, Santa Hose Summit Pain Alliance, Santa Hose Hose Hose Hose Hose Hose Hose Hose Hose	Lickensiny, Cleveland, OH, USA;
<ul> <li>Centra Rain Rainero, Santa Rosa, Los Gortes, Cane Western 1 Summit Rain Alliance, Santa Rosa, Los Gortes, Cane Western 1 University Hospitala Cleveland Medical Center, Cane Western Reser 1 Veteran Administration Medical Center, Lone Western Reser 1 Veteran Administration Medical Cane Medicine, Johns Hopkins 1 Anesthesikology and Ortikal Care Medicine, Johnson Hopkins 1 Anesthesikology and Anesthesikology and Anesthesikology 1 Anesthesikology and Anesthesikology 1 Anesthesikology and Anesthesikology 1 Anesthesikology and Anesthesikology 1 Anest</li></ul>	Inversity School of Medicine, water
<sup>5</sup> Mayo Cambado and Canada Cambado and Cambado and Cambado and Canada Cambado and Canada Cambado and Canada Cambado and Ca	/SA: ve of Medicine, Lexington, KY, USA;
** AneithenBuogy †* Department of Annethenia, UC San Diago, Anton †* Department of Annethenia, UC San Diago, Anton †** UK HealthCare Pain Services, University of Kentucky Colleg †** Maintais Neuroscience Institute, Boca Baton, FL, USA 1*** Center for the Rehabilitation of Pain Syndemmes (CIPS) at 1*** Center for the Rehabilitation of Pain Syndemmes (CIPS) at 1************************************	a Madical Plaza, Los Angeles, CA, USA;
** UK Heartman Reuroscience Institute, Boca Rature ** Marcus Neuroscience Institute, Boca Rature ** Marcus Neuroscience Institute, Boca Rature *** UK Heartman Reuroscience Institute, Boca Rature **** UK Heartman Reuroscience Institute, Boca Rature ************************************	ULLA MARCELLA
** UK Hearoscience Inditute, docal Syndromes (CRP5) at 55 Marcus Neuroscience Inditute, docal Syndromes (CRP5) at 19 Center for the Rehabilitation of Pain Syndromes (CRP5) at 19 Center for the Rehabilitation of Pa	nia. San Diego, C.A. USA:

wher frit on

	Accepted July 6, 2016
tection.	d May 1, 20% Revised Leve 3, 20% Accessed July 6, 200
(onlin	
COLUMN T	he Polyanalgesic Consensus Contenting of PACC): Recommendations for Trialing of PACC): Recommendations for Therapy
T	he Polyanalyes a lations for Trialing of
1	Recommendation Therapy
1	Hattic Com M Havek, MD, PhD'; Jason D PhD, MBA**;
Т	ntrathecal Diug Deserver, MD, PhD <sup>+</sup> ; Jason E. Pope, MD <sup>+</sup> , imothy R. Deer, MD <sup>+</sup> ; Salim M. Hayek, MD <sup>+</sup> ; Jay S. Grider, DO, PhD, MBA <sup>++</sup> ; im J. Lamer, MD <sup>6</sup> ; Maged Hamza, MD <sup>6</sup> ; Jay S. Grider, DO, PhD, MBA <sup>++</sup> ; im J. Lamer, MD <sup>6</sup> ; Maged Hamza, MD <sup>6</sup> ; MD, PhD <sup>++</sup> ; Christophe Perruchoud, MD, PhD <sup>6</sup> im States, MD <sup>1+</sup> ; Samir Narouze, MD <sup>+++</sup> ; Eric Grigsby, MD, MBA <sup>++</sup> ; im States, Michael Saulino, MD, PhD <sup>6</sup> im States, Michael Saulino, MD, PhD <sup>6</sup>
S	teven M. mson, MBBS"; Marchuss, Jacobs, PhD999; Michael Juntoon, MD9999;
	Simoli the phD+++ Main the statt +++++ Elliot March
1	Daniel With Double Phillip Nilly mine ph D#####
1	Paul Christo, MD 1991, Nagy Mekhali, Hier, and in the algorithm to treat refractory cannot drug delivery
	Elliot Ri carte patiente appropriate and propriate patiente appropriate use of the
	ductions Intrathecal (II) drug steps/methodology for a sur on best practices for data
	noncancer pain. The decision remplicated. Therefore, a consentation, address the deficiencies and emerge
	systems is controverse the string trialing this therapy before the Conference (PACC) update was designed to blications available since the panel
	intustriming the second s
	ion innovations since the previous MACL Sources were contributed by unit
	ing microsoften in 2014, and research degrees of recommendational the pace recommendations to
	trialing are presented in 34 consensus particular settings and monitorial scenarios in which IT trialing to the PACC recom-
	the action practices; measurements singly, the PACC describes chicking of trialing for IDDS impaires the
	eace Comments The strating for IT drug developments and cover stalling for Immonizing management of stypes presented in 34 comments of purposes tail satetings and immonizing management of stypes in equivalence of the strategies
	Conclusion: that no trial may be required in certain performance of the solution of the soluti
	and that of stychological evaluations and that and a style of stychological evaluations on the style course <b>Conclusters</b> . The PACC provides conservants guidance on best pice course mends that no trial may be required in contral patients populations; Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ste 100, Cheleston, WJ, USA, Enak DoctDeered Address correspondence to Trianship R. Dee, MO, President and CEO, The Center for Pain Med, Vic., 400 Court Steed, Ster 100, Cheleston, WJ, USA, Enak DoctDeered No. 2000, Steed
	A deers correspondence to: Timothy R. Uren, Mun.
	Addess Conception askcom
	for Pain Relief, Chadreston, Wy, USA.
	<ul> <li>Centro Iso: Medical Center, Cala</li> <li>Hopptala Case Medical Center, Santa Rosa CA, USA</li> <li>Summit Pain Allance, Santa Rosa CA, USA</li> <li>Summit Pain Allance, Santa Rosa CA, USA</li> <li>Canada Center, Richmond, VA, USA;</li> </ul>
	Summing Chric Rochester, MN, USA Manao Chric Rochester, MN, USA
	<ul> <li>Majo &amp; Commonwells University of Retricted Component</li> <li>Vigita Care Pain Service, University of Retricted Component</li> <li>URNetableCare Pain Service, PAI, SAA</li> <li>Tobumar Valley Pain &amp; Spine Institut, CAB Mong, PA, ISA</li> <li>Tobumar Valley Pain &amp; Spine Institut, CAB Mong, PA, ISA</li> </ul>
	** UK-treate Valley Pair & Spree mixed on the Spree
	+t Weitern weise Morges, Morges, Weiterstein PHT, Essex, UK;
	<ul> <li>Hopfau Ge. Diversity Hopfaulty Ho</li></ul>
1	+++ Hunter Fair - chairal Research, Napa
1	err Doley's Creater Los Auguste
1	His California reading and the second s
1	
1	1111 Bayn Mawr Hospital, Bryn mewr All SA 1111 Bayn Mawr Hospital, Neuark, DE, USA 1112 Christiana Hospital, Neuark, DE, USA

unuary 2017, after first online publication: the name of the second a

tulation: Technology at the Neur

Hayek" to "Salim M. Hayel

ten corrected from "Salim I.

author has be

© 2017 International Neuromodulation Society

Painweek PACC, Polyanalgesic Consensus Conference. Deer TR, et al. Neuromodulation. 2017;20(2):96-132; Deer TR, et al. Neuromodulation. 2017;20(2):133-154; Deer TR, et al. Neuromodulation. 2017;20(2):155-176

© 2017 International Neuromodulation Society

and and T

# Patient Selection for Intrathecal Therapy: Disease State Indications



- FDA approvals for intrathecal morphine and ziconotide
  - -Management of severe chronic pain (no specific diagnoses)
- Potential clinical scenarios
  - Axial pain
    - Failed back surgery syndrome
    - Vertebral compression fractures
    - Refractory facet arthropathy, spondylosis, nonoperative spondylolisthesis
  - Extremity pain
    - Radiculopathy following failed back surgery
    - Radiculopathy that cannot be addressed with surgery

- Visceral pelvic or abdominal pain
- Complex regional pain syndrome
- Postsurgical or traumatic nerve damage
- Peripheral neuropathies
- Cancer pain
- End-of-life pain

FDA, US Food and Drug Administration.

Deer TR, et al. Neuromodulation. 2012;15(4):420-435; Deer TR, et al. Pain Physician. 2010;13(3):E175-E213; Deer TR, Pope JE. Expert Rev Clin Pharmacol. 2015;8(5)507-510;

### **Patient Selection: PACC Recommendations**

Statement	Evidence Level	Recommendation Grade	Consensus level
Localized pain can be adequately covered with intrathecal therapy	II	В	Strong
Diffuse pain can be adequately treated with intrathecal therapy	Ш	С	Moderate
Global pain can be adequately treated with intrathecal therapy	III	D	Moderate
Intrathecal therapy should not be used as salvage therapy for failing systemic <u>opioids</u> <sup>a</sup>	II	В	Moderate

<sup>3</sup>Sustained success more likely when patients are weaned off opioids before trialing; different titration schedules have been recommended. Deer TR, et al. *Neuromodulation*. 2017;20(2):96-132.



# Patient Selection: Important Patient Characteristics

- Well-managed comorbidities
  - Intrathecal opioids require increased vigilance for patients with comorbidities that negatively affect cardiopulmonary function
- Sufficiently fit for surgery
- Autonomous with a good understanding of intrathecal therapy and other treatment options
  - -Can be addressed with strong social structure
- Appropriate psychological status
- Ability to comply with requirements of care, including office visits for refills

### Patient Selection:

### **Potential Complicating Issues in Intrathecal Therapy**

- Consider comorbidities that increase risks (no absolute contraindications)
  - -Sleep apnea
  - -Obesity or metabolic syndrome
  - -Diabetes
    - Poor wound healing and increased surgical-site infections
  - -Coagulopathies and anticoagulant therapy
  - -Chronic lung disease
  - -Reduced cardiac function
  - -Immunocompromised status
  - -Substance abuse issues

### Drug Selection: Intrathecal Options for Pain Management

Drug	Recommended Starting Dosage	Maximum Concentration	Maximum Dose/Day
Morphine	0.1–0.5 mg/day	20 mg/mL	15 mg
Hydromorphone	0.01–0.15 mg/day	15 mg/mL	10 mg
Ziconotide	0.5–2.4 µg/day	100 µg/mL	19.2 µg
Fentanyl	25–75 µg/day	10 mg/mL	1000 µg
Bupivacaine	0.01–4 mg/day	30 mg/mL	15–20 mg <sup>a</sup>
Clonidine	20–100 µg/day	1000 µg/mL	600 µg
Sufentanil	10–20 µg/day	5 mg/mL	500 µg

<sup>3</sup>May be exceeded in end-of-life care and complicated cases as determined by medical necessity. Deer TR, et al. *Neuromodulation*. 2017;20(2):96-132.

### Intrathecal Drug Selection: 2016 Guideline Recommendations For Nociceptive/Neuropathic Noncancer Pain

Line	Recommended Regimens		Line	Recomment	ded Regimens
<b>1</b> A	<ul> <li>Ziconotide</li> </ul>	Morphine	<b>1A</b>	Morphine	<ul> <li>Ziconotide</li> </ul>
1B	• Fentanyl	<ul> <li>Fentanyl + Bupivacaine</li> </ul>	1B	Hydromorphone	Morphine or Hydromorphone +
2	<ul> <li>Fentanyl + Clonidine</li> <li>Fentanyl + Bupivacaine +</li> <li>Hvdromorphone or</li> <li>Clonidine</li> </ul>			Bupivacaine     Fentanyl + Bupivacaine	
	<ul> <li>Hydromorphone or Morphine + Bupivacaine</li> </ul>	Bupivacaine		<ul> <li>Ziconotide + Morphine or Hydromorphone</li> </ul>	
3	<ul> <li>Fentanyl + Ziconotide + Clonidi</li> <li>Morphine or Hydromorphone +</li> <li>Ziconotide + Clonidine or Bupiv</li> <li>Bupivacaine + Clonidine</li> </ul>	Clonidine	3	<ul> <li>Hydromorphone or Morphine + Bupivacaine + Clonidine</li> <li>Fentanyl + Ziconotide</li> </ul>	<ul> <li>Sufentanil + Bupivacaine or Clonidine</li> <li>Ziconotide + Clonidine or</li> </ul>
4	<ul> <li>Sufentanil + Bupivacaine or Clo</li> <li>Baclofen</li> <li>Bupivacaine + Clonidine + Zico</li> </ul>		4	<ul> <li>Fentanyl or Sufentanil + Bupivacaine + Clonidine</li> </ul>	<ul> <li>Bupivacaine or Both</li> <li>Sufentanil + Ziconotide</li> <li>Baclofen</li> </ul>
5	<ul> <li>Sufentanil + Bupivacaine + Clonidine</li> <li>Sufentanil + Ziconotide</li> </ul>		5	Opioid + Ziconotide + Bupivaca	ine or Clonidine

Deer TR, et al. Neuromodulation. 2017;20(2):96-132.

#### Intrathecal Drug Selection 2016 Guideline Recommendations for Nociceptive/Neuropathic Cancer-Related Pain

LUCAIIZEU Faili				Dilluse Falli		
Line	Recommen	ded Regimens	Line	Recom	mended Regimens	
<b>1A</b>	Ziconotide	Morphine	<b>1</b> A	<ul> <li>Ziconotide</li> </ul>	Morphine	
1B	<ul> <li>Fentanyl</li> <li>Morphine or Fentanyl + Bug</li> </ul>	pivacaine	1B	<ul> <li>Hydromorphone</li> <li>Morphine or Hydromo</li> </ul>	rphone + Bupivacaine	
2	<ul> <li>Hydromorphone</li> <li>Hydromorphone or Fentanyl or</li> </ul>	<ul> <li>Hydromorphone + Bupivacaine</li> <li>Morphine or Hydromorphone or</li> </ul>	<ul> <li>Hydromorphone or Morphine + Clonidine</li> <li>Morphine or Hydromorphone + Ziconotide</li> </ul>			
	Morphine + Clonidine	Fentanyl + Ziconotide		Hydromorphone or Morphi	• Hydromorphone or Morphine or	
3	<ul> <li>Hydromorphone or Morphine or Fentanyl + Bupivacaine + Clonidine</li> <li>Ziconotide + Bupivacaine</li> </ul>	ivacaine + Inivacaine + Inivacaine + Inivacaine + Inivacaine + Inivacaine +	3	Fentanyl + Bupivacaine + Clonidine • Ziconotide + Bupivacaine • Ziconotide + Clonidine	Fentanyl + Bupivacaine + Ziconotide • Sufentanil	
	<ul> <li>Ziconotide + Clonidine</li> </ul>	Sufentanil		Sufentanil + Ziconotide	<ul> <li>Bupivacaine + Clonidine +</li> </ul>	
4	<ul> <li>Sufentanil + Ziconotide</li> <li>Sufentanil + Bupivacaine</li> <li>Baclofen</li> </ul>	<ul> <li>Bupivacaine + Clonidine + Ziconotide</li> </ul>	4	4	<ul> <li>Baclofen</li> <li>Sufentanil + Bupivacaine</li> <li>Sufentanil + Clonidine</li> </ul>	Ziconotide • Bupivacaine + Clonidine
	Sufentanil + Clonidine	Bupivacaine + Clonidine	5	<ul> <li>Sufentanil + Bupivacaine + Clonidine</li> <li>Sufentanil + Bupivacaine + Ziconotide</li> </ul>		
5	Sufentanil + Bupivacaine + Clonic	dine	Suferitanii + Bupivacane + Ziconotide     Suferitanii + Clonidine + Ziconotide			
6	• Opioid + Bupivacaine + Clonidine + Adjuvants			Opioid + Bupivacaine + Clonidine + Adjuvants		
	•			Sufentanil + Clonidine + Zio		

Localized Pain

#### Diffuse Pain

Deer TR, et al. Neuromodulation. 2017;20(2):96-132.



# FDA-APPROVED INTRATHECAL ANALGESICS

# Morphine

- µ-Opioid receptor agonist
- Most serious AE is respiratory depression
  - Risk increased with other agents that depress the CNS
    - (eg, benzodiazepines)

# Ziconotide

- N-type Ca<sup>2+</sup> channel blocker
- Most serious AEs are neurocognitive
  - -eg, confusion, dizziness, hallucinations
  - Urinary retention also can lead to treatment discontinuation

AE, adverse event; CNS, central nervous system.

Coffey RJ, et al. *Anesthesiology*. 2009;111(4):881-891; Deer TR, et al. *Neuromodulation*. 2012;15(5):436-466; Prager JT, et al. *Neuromodulation*. 2014;17(4):354-372;

Webster LR, et al. J Pain Symptom Manage. 2009;37(3):363-372.



# INTRATHECAL MORPHINE Overview




- Recommended starting dose
  - -0.1 to 0.5 mg/day

آخر ا

- Recommended maximum dose
  - -15 mg/day (concentration, 20 mg/mL)
- Monitoring for granuloma formation is essential
- Consider endocrine evaluation before initiation and periodically during therapy
  - -Treatment-related hypogonadism may reduce libido, mood, and bone density (with increased fracture risk)
  - -Consider estrogen/testosterone replacement, if needed
- AEs may include respiratory depression, fluid retention, urinary retention, sedation, pruritus, and endocrine and immunologic issues

Deer TR, et al. *Neuromodulation*. 2017;20(2):96-132; Prager JT, et al. *Neuromodulation*. 2014;17(4):354-372; Webster LR, et al. *J Pain Symptom Manage*. 2009;37(3):363-372.

# Intrathecal Opioids Analgesia and Function



Bars are 95% Cls.


NWEEK.

Pai

BPI, Brief Pain Inventory; CI, confidence interval. Hamza M, et al. *Pain Med*. 2012;13(10):1304-1313.

# Intrathecal Opioids Long-Term Outcomes


Painweek.



N=20 patients with chronic nonmalignant pain (17 lower back, 1 abdominal, 1 spinal, 1 leg) treated with intrathecal opioids.

Duarte RV, et al. J Neurosurg Anesthesiol. 2012;24(1):63-70.

# **Opioids + Bupivacane Analgesia and Dosing**



Patients with chronic noncancer pain treated with an intrathecal opioid (n=72) or an intrathecal opioid and bupivacaine (n=54). Veizi IE, et al. Pain Med. 2011;12(10):1481-1489.



### **Intrathecal Ziconotide**




- For use in the SynchroMed II Infusion System and CADD-Micro Ambulatory Infusion Pumps
- Recommended starting dose: 0.5 to 2.4 µg/day
- Recommended maximum dose: 19.2 µg/day
- AEs include sedation, somnolence, nausea, headache, and lightheadedness
- Not associated with granuloma formation or overdose
- New PACC recommendations: unless contraindicated, intrathecal ziconotide should be considered as an alternative to opioids, and in certain circumstances, should be considered first-line therapy

Deer TR, et al. *Neuromodulation*. 2017;20(2):96-132; Deer TR, et al. *Neuromodulation*. 2017;20(2):133-154; Dupoiron D, et al. *Pain Physician*. 2012;15(5):395-403; Prager J, et al. *Neuromodulation*. 2014;17(4):354-372; Webster LR, et al. *J Pain Symptom Manage*. 2009;37(3):363-372.



### **INTRATHECAL ZICONOTIDE** *Evidence of Efficacy*




VASPI, Visual Analog Scale of Pain Intensity.

N=457 patients in 3 double-blind, placebo-controlled studies (268 ziconotide, 189 placebo).

Collins R, et al. Effectiveness of intrathecal ziconotide in multiple pain etiologies: a meta-analysis of three controlled trials. Presented at the 21st Annual Meeting of the American An

# Intrathecal Ziconotide Evidence of Efficacy



VASPI, Visual Analog Scale of Pain Intensity.

N=457 patients in 3 double-blind, placebo-controlled studies (268 ziconotide, 189 placebo).

Collins R, et al. Effectiveness of intrathecal ziconotide in multiple pain etiologies: a meta-analysis of three controlled trials. Presented at the 21st Annual Meeting of the American Academy of Pain Medicine; February 23-27, 2005; Palm Springs, CA. Abstract 159.




# Intrathecal Trials Overview

- Purpose of intrathecal trials
  - -Evaluate potential pain relief
  - -Gauge patient's level of commitment to treatment
- Specific methods vary
  - -Single injection
  - -Continuous infusion
  - -Intermittent boluses
- No evidence that trial results predict outcomes
  - No particular trialing method has been associated with better prediction of long-term benefits
- Trialing doses should be conservative

Deer TR, et al. Pain Physician. 2010;13(3):E175-E213; Deer TR, et al. Neuromodulation. 2017;20(2):133-154; Prager J, et al. Neuromodulation. 2014;17(4):354-372.


# **INTRATHECAL TRIALS**

#### Intermittent Boluses vs Continuous Infusion



N=40 patients assigned to trialing with either intermittent boluses or continuous infusion of opioids; 1-patient in each group failed the trial (<50% pain relief).

# Intrathecal Trials Intermittent Boluses vs Continuous Infusion



N=40 patients assigned to trialing with either intermittent boluses or continuous infusion of opioids; 1 patient in each group failed the trial (<50% pain relief). Hamza M, et al. *Neuromodulation*. 2015;18(7):636-649.

# Intrathecal Therapy Potential Complications

- Pump failure
- Hemorrhage leading to spinal hematoma
- Wound infection
- CSF leakage

- Catheter-related complications
  - Dislodgement or migration from intrathecal space
  - Fracture or breakage
  - Kink or occlusion
  - Puncture or cut
- Granulomas
  - Inflammatory masses at the catheter tip

# **SCS Complications**

- Hardware complication- most common with SCS. Less with paddle leads, and also less of an issue with new technology. With new leads/programming, revision rates for this complication dropped to 4% from 15%
- Pain at surgical site
- Lead migration
- Thoracic radiculopathy- 2% ? Pre-op MRI
- Infection
- Serious neurologic sequelae (ie hematoma)- very rare



# Conclusions

- Multiple approaches to neuromodulation are currently available and in use
- Identifying best approach for indivual patients remains challenging
- Steps can be taken to optimize patient selection



### **Thank You!**



